Menu Search
Equities

Dermapharm Holding SE

DMPX:GER

Dermapharm Holding SE

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (EUR)37.50
  • Today's Change0.600 / 1.63%
  • Shares traded55.74k
  • 1 Year change-5.73%
  • Beta0.9504
Data delayed at least 15 minutes, as of Nov 21 2024 16:35 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
Select bar for recommendation details.
Recommendations14-Nov-24
Buy1
Outperform4
Hold0
Sell0
Strong Sell0

Share price forecast in EUR

The 4 analysts offering 12 month price targets for Dermapharm Holding SE have a median target of 49.50, with a high estimate of 50.00 and a low estimate of 41.50. The median estimate represents a 32.00% increase from the last price of 37.50.
High33.3%50.00
Med32.0%49.50
Low10.7%41.50

Dividends

In 2023, Dermapharm Holding SE reported a dividend of 0.88 EUR. The 5 analysts covering the company expect dividends of 0.98 EUR for the upcoming fiscal year, an increase of 11.36%.
Div growth (TTM)--
More ▼

Earnings history & estimates in EUR

On Aug 31, 2022, earnings of 0.270 per share.
The next earnings announcement is expected on Mar 31, 2025.
Average growth rate-8.75%
Dermapharm Holding SE reported annual 2023 earnings of 1.16 per share on Mar 28, 2024.
Average growth rate+16.61%
More ▼

Revenue history & estimates in EUR

Dermapharm Holding SE had 3rd quarter 2024 revenues of 311.60m. This bettered the 296.30m estimate of the one analyst covering the company. This was 2.35% below the prior year's 3rd quarter results.
Average growth rate+2.66%
Dermapharm Holding SE had revenues for the full year 2023 of 1.14bn. This was 10.79% above the prior year's results.
Average growth rate+12.88%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.